NVTA News and Press, Invitae Corporation From 11/08/23

Invitae Reports Third Quarter 2023 Financial Results PR Newswire Reported revenue of $121.2 million , a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4% Gross margin of 32.2% an...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Invitae Corporation (NVTA) is expected to report $-0.3 for Q3 2023

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships PR Newswire – Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies –...

2023-11-04 09:59:00 ET Genetic-testing company, Invitae (NYSE: NVTA) , isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and renegotiating some of its debt, there's been a lot of activity which ...

Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 PR Newswire SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third q...

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results PR Newswire – Findings set to enhance patient care and reduce uncertainty in test results as clinicians...

2023-10-19 16:36:27 ET More on Invitae Invitae: Revenue Troubles Build Biggest stock movers today: Arch Resources, Coinbase Global and more Invitae jumps as FDA clears first-of-its-kind cancer test For further details see: Invitae appoints David Sholehvar...

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer PR Newswire SAN FRANCISCO , Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholeh...

Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer PR Newswire – Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines – &#...